Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer.

IF 2.4 3区生物学 Q2 MULTIDISCIPLINARY SCIENCES

PeerJ Pub Date : 2025-10-08 eCollection Date: 2025-01-01 DOI:10.7717/peerj.19968

Lijin Zhang, Aiping Lin, Jie Lin, Juan Chen, Mengshi Chen, Xunbin Yu, Yijuan Wu, Tao Wang, Yan Lu, Zhaofen Ba, Xiaowei Cheng, Tiantian Zhang, Minghong Chen

{"title":"Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer.","authors":"Lijin Zhang, Aiping Lin, Jie Lin, Juan Chen, Mengshi Chen, Xunbin Yu, Yijuan Wu, Tao Wang, Yan Lu, Zhaofen Ba, Xiaowei Cheng, Tiantian Zhang, Minghong Chen","doi":"10.7717/peerj.19968","DOIUrl":null,"url":null,"abstract":"Background: To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer.Methods: The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specific quantitative polymerase chain reaction (PCR).Results: In tissue samples, the NEUROG1 methylation detection rates were 36% for CRC, 24% for NAA, and 88% for AA. In stool samples, the NEUROG1 methylation detection had a sensitivity of 63.46% for CRC with a positive predictive value (PPV) of 85.94%. The overall diagnostic specificity of the test for the NAA and the healthy control was 76.32%, with a negative predictive value (NPV) of 40.28%.Conclusion: NEUROG1 methylation detection can potentially be used in the CRC and AA screening.","PeriodicalId":19799,"journal":{"name":"PeerJ","volume":"13 ","pages":"e19968"},"PeriodicalIF":2.4000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12514994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PeerJ","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.7717/peerj.19968","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer.

Methods: The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specific quantitative polymerase chain reaction (PCR).

Results: In tissue samples, the NEUROG1 methylation detection rates were 36% for CRC, 24% for NAA, and 88% for AA. In stool samples, the NEUROG1 methylation detection had a sensitivity of 63.46% for CRC with a positive predictive value (PPV) of 85.94%. The overall diagnostic specificity of the test for the NAA and the healthy control was 76.32%, with a negative predictive value (NPV) of 40.28%.

Conclusion: NEUROG1 methylation detection can potentially be used in the CRC and AA screening.

查看原文本刊更多论文

晚期腺瘤和结直肠癌患者粪便标本中NEUROG1甲基化状态的评估。

背景：评估晚期腺瘤和结直肠癌中NEUROG1甲基化的状态。方法：采用甲基化特异性定量聚合酶链式反应（PCR）技术检测结直肠癌（CRC）、晚期腺瘤（AA）和非晚期腺瘤（NAA）患者组织和粪便样本中NEUROG1的甲基化水平。结果：在组织样本中，CRC的NEUROG1甲基化检出率为36%，NAA为24%，AA为88%。在粪便样本中，NEUROG1甲基化检测对CRC的敏感性为63.46%，阳性预测值（PPV）为85.94%。对NAA及健康对照者的诊断特异性为76.32%，阴性预测值（NPV）为40.28%。结论：NEUROG1甲基化检测可用于CRC和AA筛查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PeerJ MULTIDISCIPLINARY SCIENCES-

CiteScore

4.70

自引率

3.70%

发文量

1665

审稿时长

10 weeks

期刊介绍： PeerJ is an open access peer-reviewed scientific journal covering research in the biological and medical sciences. At PeerJ, authors take out a lifetime publication plan (for as little as $99) which allows them to publish articles in the journal for free, forever. PeerJ has 5 Nobel Prize Winners on the Board; they have won several industry and media awards; and they are widely recognized as being one of the most interesting recent developments in academic publishing.